Siga Technologies Blames Ch. 11 On Appeal Bond
Smallpox drug manufacturer Siga Technologies Inc. won't be able to appeal a potential $232 million judgment stemming from a failed merger and subsequent licensing litigation without Chapter 11 protection, the defense...To view the full article, register now.
Already a subscriber? Click here to view full article